What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Feline Hypereosinophilic Syndrome: Diagnosis and Management

Feline hypereosinophilic syndrome (HES) is a progressive disorder in cats defined by persistent, severe eosinophilia and eosinophilic infiltration of multiple organs, most commonly the gastrointestinal tract, respiratory system, and skin. This condition requires differentiation from other causes of eosinophilia including parasitic infections, allergic disease, eosinophilic granuloma complex, and eosinophilic leukemia. Diagnosis depends on a complete blood count, bone marrow aspirate, and histopathology of affected tissues. Management typically involves corticosteroids and may include hydroxyurea or imatinib, though prognosis is guarded. This article provides veterinarians with evidence-based guidance on differentiating HES from other eosinophilic conditions and implementing appropriate management strategies.

At a Glance: Feline Hypereosinophilic Syndrome

Feature	Hypereosinophilic Syndrome	Eosinophilic Leukemia	Parasitic or Allergic Eosinophilia
Eosinophil count	Persistent, severe (>5,000/µL)	Variable, often very high	Usually mild to moderate, resolves with treatment
Organ infiltration	Multiorgan (GI, respiratory, skin, heart)	Bone marrow and extramedullary sites	Limited to affected organ system
Response to corticosteroids	Partial or transient	Poor	Good, with resolution of underlying cause
Bone marrow findings	Eosinophilic hyperplasia without blasts	Blast cells, dysplastic changes	Reactive eosinophilia
Prognosis	Guarded to poor	Poor	Good with appropriate treatment

Pathophysiology and Etiology

Feline hypereosinophilic syndrome results from dysregulated production of eosinophils by the bone marrow, driven by abnormal cytokine signaling, particularly interleukin-5. The eosinophils themselves are morphologically normal but infiltrate tissues and release cytotoxic granules that cause tissue damage and fibrosis. The underlying trigger for this dysregulation is not fully understood, but it may involve clonal expansion of eosinophil precursors or aberrant T-cell responses.

The condition is considered idiopathic when no underlying cause is identified. However, a paraneoplastic form has been described in association with lymphocytic intestinal lymphoma, as reported in a case of feline paraneoplastic hypereosinophilic syndrome associated with lymphocytic intestinal lymphoma (Brazilian journal of veterinary medicine, 2026). This highlights the importance of thorough diagnostic investigation to rule out occult neoplasia.

Clinical Signs and Presentation

Feline hypereosinophilic syndrome typically presents with nonspecific clinical signs that reflect the organs affected by eosinophilic infiltration. The most common presentation involves the gastrointestinal tract, with chronic vomiting, diarrhea, weight loss, and anorexia. Respiratory signs include coughing, dyspnea, and tachypnea due to pulmonary infiltration. Dermatologic signs may include pruritus, alopecia, and eosinophilic plaques or granulomas.

Cardiac involvement is less common but has been documented, including a case of hypereosinophilic syndrome with cardiac infiltration and congestive heart failure in a cat (Journal of veterinary cardiology, 2022). This underscores the potential for life-threatening complications and the need for comprehensive evaluation.

Clinical signs are often progressive and may wax and wane. Affected cats are typically middle-aged to older, with no clear breed or sex predilection. The onset is usually insidious, and many cats have had signs for weeks to months before presentation.

Diagnostic Workup

Complete Blood Count and Biochemistry

The hallmark laboratory finding is persistent, severe eosinophilia, often exceeding 5,000 eosinophils per microliter. Eosinophils appear morphologically normal on blood smear. Other CBC abnormalities may include mild anemia, thrombocytopenia, or leukocytosis. Serum biochemistry may reveal elevated liver enzymes, hypoalbuminemia, or hyperglobulinemia, reflecting organ involvement.

It is essential to rule out other causes of eosinophilia, including parasitic infections (e.g., heartworm, lungworm, gastrointestinal parasites), allergic disease, eosinophilic granuloma complex, and drug reactions. Fecal examination, heartworm testing, and thorough history taking are critical.

Bone Marrow Aspirate and Biopsy

Bone marrow examination is essential to differentiate HES from eosinophilic leukemia. In HES, the bone marrow shows eosinophilic hyperplasia with a normal maturation sequence and no evidence of blast cells or dysplastic changes. In eosinophilic leukemia, blast cells are present, and there may be dysplastic features in other cell lines.

Bone marrow aspirate should be performed under sedation or anesthesia, typically from the proximal femur or humerus. Samples should be submitted for cytologic evaluation. If results are equivocal, core biopsy may provide additional diagnostic information.

Histopathology of Affected Tissues

Tissue biopsy is often necessary to confirm the diagnosis and assess the extent of organ involvement. Endoscopic biopsies of the gastrointestinal tract are commonly performed and reveal eosinophilic infiltration of the mucosa, submucosa, and sometimes deeper layers. Respiratory tract biopsies may show eosinophilic pneumonia or bronchitis. Skin biopsies demonstrate eosinophilic dermatitis.

Histopathology also helps rule out other conditions such as inflammatory bowel disease, lymphoma, or eosinophilic granuloma complex. In cases where paraneoplastic HES is suspected, careful examination for concurrent neoplasia, particularly lymphoma, is warranted.

Imaging

Thoracic radiographs may reveal interstitial or bronchial patterns, pulmonary infiltrates, or pleural effusion. Abdominal ultrasound may show thickened intestinal walls, mesenteric lymphadenopathy, or hepatosplenomegaly. Echocardiography is indicated if cardiac involvement is suspected, as in the case of hypereosinophilic syndrome with cardiac infiltration and congestive heart failure in a cat (Journal of veterinary cardiology, 2022).

Differential Diagnosis

Differentiating HES from other eosinophilic conditions is critical for appropriate management. The key differentials include:

Eosinophilic leukemia: Distinguished by the presence of blast cells in blood or bone marrow, dysplastic changes, and poor response to corticosteroids.
Parasitic infections: Eosinophilia resolves with appropriate antiparasitic treatment.
Allergic disease: Eosinophilia is usually mild to moderate and responds to allergen avoidance or antihistamines.
Eosinophilic granuloma complex: Lesions are typically limited to the skin or oral cavity, and systemic signs are absent.
Inflammatory bowel disease: Eosinophilic infiltration is limited to the gastrointestinal tract, and eosinophilia is usually mild.
Paraneoplastic HES: Associated with underlying neoplasia, most commonly lymphoma.

A case of hypereosinophilic syndrome in a cat (The Canadian veterinary journal, 1996) and hypereosinophilic syndrome in two cats (The Journal of veterinary medical science, 2008) illustrate the clinical presentation and diagnostic challenges.

Treatment Options

Corticosteroids

Corticosteroids are the mainstay of therapy for HES. Prednisolone or prednisone is typically administered at immunosuppressive doses, with gradual tapering based on clinical response and eosinophil counts. Many cats show initial improvement, but the response is often partial or transient. Long-term therapy is usually required, and relapses are common.

Monitoring for corticosteroid side effects, including diabetes mellitus, urinary tract infections, and gastrointestinal ulceration, is essential. Cats on long-term corticosteroids should have regular blood glucose monitoring and urinalysis.

Hydroxyurea

Hydroxyurea is a chemotherapeutic agent that inhibits DNA synthesis and can reduce eosinophil production. It is used as a second-line therapy in cats that do not respond adequately to corticosteroids or require dose reduction. Hydroxyurea is administered orally, and the dose is adjusted based on CBC monitoring.

Potential side effects include myelosuppression, gastrointestinal upset, and hepatotoxicity. Regular CBC monitoring is required to detect neutropenia or thrombocytopenia. Cats should be monitored for signs of bone marrow suppression.

Imatinib

Imatinib is a tyrosine kinase inhibitor that targets the PDGFRA and PDGFRB receptors, which are involved in eosinophil proliferation in some cases of HES. It has been used successfully in some cats, particularly those with suspected clonal eosinophil disorders. Imatinib is administered orally and is generally well tolerated.

Side effects may include gastrointestinal upset, hepatotoxicity, and myelosuppression. Monitoring of liver enzymes and CBC is recommended. Imatinib is expensive and may not be readily available.

Supportive Care

Supportive care is essential for managing clinical signs and improving quality of life. This may include dietary modification (e.g., hypoallergenic or low-residue diets), antiemetics, antidiarrheals, and bronchodilators. Fluid therapy and nutritional support may be necessary in cats with severe gastrointestinal involvement.

Monitoring and Prognosis

Clinical Monitoring

Regular monitoring of clinical signs, body weight, and appetite is essential. Cats should be re-evaluated every 2 to 4 weeks initially, then every 1 to 3 months once stable. CBC should be performed at each visit to assess eosinophil counts and detect myelosuppression from therapy.

Prognostic Factors

The prognosis for HES is guarded to poor. Most cats require lifelong therapy, and the disease is often progressive. Factors associated with a poorer prognosis include severe organ infiltration, cardiac involvement, poor response to corticosteroids, and development of myelosuppression from therapy.

A case of hypereosinophilic syndrome in a cat (The Canadian veterinary journal, 1996) and hypereosinophilic syndrome in two cats (The Journal of veterinary medical science, 2008) report variable survival times, with some cats surviving months to years with appropriate management.

Common Failure Patterns

Incomplete Diagnostic Workup

Failure to perform a complete diagnostic workup, including bone marrow aspirate and tissue biopsy, can lead to misdiagnosis and inappropriate treatment. HES must be differentiated from eosinophilic leukemia and other causes of eosinophilia.

Inadequate Corticosteroid Dosing

Insufficient corticosteroid dosing may result in poor clinical response. Immunosuppressive doses are typically required, and tapering should be gradual based on response.

Lack of Monitoring

Failure to monitor CBC and clinical signs regularly can lead to unrecognized myelosuppression from hydroxyurea or imatinib, or progression of organ infiltration.

Ignoring Paraneoplastic Possibility

HES may be paraneoplastic, particularly in association with lymphoma. Failure to investigate for underlying neoplasia can delay diagnosis and treatment of the primary condition.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internist or oncologist in the following situations:

Difficulty differentiating HES from eosinophilic leukemia or other eosinophilic disorders
Poor response to corticosteroid therapy
Need for second-line therapies such as hydroxyurea or imatinib
Development of severe side effects from therapy
Suspected cardiac involvement
Evidence of concurrent neoplasia

Practical Decision Framework for Managing Feline Hypereosinophilic Syndrome

Treatment Response Stratification and Escalation Protocol

Managing feline hypereosinophilic syndrome requires a structured approach to treatment decisions, as individual cats vary considerably in their response to therapy. A systematic framework helps veterinarians make consistent, evidence-informed choices while avoiding common pitfalls that lead to treatment failure. This section provides a practical decision framework based on clinical response categories, a record system for tracking disease progression, and troubleshooting methods for common management challenges.

Response Categories and Treatment Tiers

Categorize each cat into one of three response groups after four weeks of initial therapy. This stratification guides subsequent treatment decisions and helps identify cats that require escalation to second-line therapies.

Complete Responders: Cats showing resolution of clinical signs and normalization of eosinophil counts (less than 1,500 eosinophils per microliter) after four weeks of corticosteroid therapy. These cats typically maintain remission on tapering doses of prednisolone. Taper the corticosteroid dose by 25 percent every two to four weeks, monitoring clinical signs and CBC before each dose reduction. The goal is to identify the lowest effective maintenance dose. Many cats require 0.5 to 1 mg/kg of prednisolone every other day for long-term control. Document the maintenance dose and the time required to reach it, as this information guides future management if relapse occurs.

Partial Responders: Cats showing improvement in clinical signs but persistent eosinophilia (1,500 to 5,000 eosinophils per microliter) or incomplete resolution of organ-specific signs after four weeks. These cats require careful evaluation to determine whether the current corticosteroid dose is adequate or whether additional therapy is needed. Consider increasing the corticosteroid dose by 25 to 50 percent and reassessing in two weeks. If clinical signs improve but eosinophilia persists, continue the current dose and monitor closely. If clinical signs do not improve with dose escalation, proceed to second-line therapy.

Non-Responders: Cats showing no improvement or worsening of clinical signs after four weeks of corticosteroid therapy, regardless of eosinophil count. These cats require immediate investigation for alternative diagnoses, including eosinophilic leukemia, paraneoplastic HES, or concurrent disease. Perform a repeat bone marrow aspirate, abdominal ultrasound, and tissue biopsies if not already done. Consider referral to a veterinary internist. Initiate second-line therapy with hydroxyurea or imatinib while awaiting diagnostic results.

Record System for Disease Monitoring

Maintain a standardized record for each cat with HES to track disease progression and treatment response. The following elements should be documented at each recheck visit:

Clinical Score (0 to 10): Assign a subjective score based on the owner's assessment of the cat's appetite, activity level, vomiting frequency, stool quality, and respiratory effort. A score of 0 represents normal, and 10 represents the worst clinical signs observed at diagnosis. This simple numeric scale helps owners communicate changes between visits and provides a consistent metric for treatment decisions.

Eosinophil Count Trend: Record the absolute eosinophil count at each visit and plot it on a graph to visualize trends. A rising count despite stable clinical signs may indicate impending relapse. A falling count with persistent clinical signs may suggest that organ infiltration is not fully controlled by eosinophil reduction alone.

Body Weight: Weigh the cat at each visit and record the weight in kilograms. Weight loss is an early indicator of disease progression or inadequate treatment response. Weight gain suggests improvement in gastrointestinal function and overall disease control.

Corticosteroid Dose: Record the current prednisolone dose in mg per kg per day or every other day. Note any dose changes and the reason for the change.

Second-Line Therapy Details: If using hydroxyurea or imatinib, record the dose, frequency, and any dose adjustments. Note the date of initiation and the reason for adding the medication.

Side Effect Monitoring: Document any observed or reported side effects from therapy, including polyuria, polydipsia, vomiting, diarrhea, lethargy, or signs of infection. Record the results of blood glucose monitoring, urinalysis, and CBC as appropriate.

Imaging Findings: Record the results of any imaging studies performed, including thoracic radiographs, abdominal ultrasound, or echocardiography. Note changes from previous studies.

Troubleshooting Common Management Challenges

Challenge 1: Persistent Eosinophilia Despite Clinical Improvement

Some cats show marked clinical improvement on corticosteroids but maintain eosinophil counts above 5,000 per microliter. This dissociation between clinical signs and laboratory values creates uncertainty about whether to escalate therapy. In these cases, prioritize clinical response over laboratory values. If the cat is eating well, maintaining weight, and showing no signs of organ dysfunction, continue the current corticosteroid dose and monitor. The eosinophil count may gradually decrease over weeks to months. However, if clinical signs recur while eosinophilia persists, consider adding second-line therapy.

Challenge 2: Relapse During Corticosteroid Tapering

Relapse during dose reduction is common and does not necessarily indicate treatment failure. Increase the corticosteroid dose to the previous effective level and stabilize the cat for two to four weeks before attempting a slower taper. Reduce the dose by 10 to 20 percent every four weeks instead of the standard 25 percent reduction. If relapse occurs again at a low dose, consider adding hydroxyurea or imatinib to allow further corticosteroid reduction.

Challenge 3: Poor Tolerance of Corticosteroids

Cats that develop significant side effects from corticosteroids, such as diabetes mellitus, severe polyuria and polydipsis, or behavioral changes, require dose reduction or alternative therapy. Measure blood glucose and urine glucose at each recheck visit. If diabetes develops, manage with insulin therapy and reduce the corticosteroid dose as much as possible. Consider adding hydroxyurea or imatinib early to allow corticosteroid dose reduction. In some cases, switching to a different corticosteroid formulation, such as dexamethasone, may reduce side effects, though this should be done cautiously and with monitoring.

Challenge 4: Myelosuppression from Hydroxyurea

Hydroxyurea can cause dose-dependent myelosuppression, particularly neutropenia and thrombocytopenia. Monitor CBC every two weeks for the first two months of therapy, then monthly once stable. If the neutrophil count falls below 2,000 per microliter or the platelet count falls below 100,000 per microliter, reduce the hydroxyurea dose by 25 to 50 percent and recheck CBC in one week. If counts do not improve, discontinue hydroxyurea and consider imatinib or other alternatives. Always inform owners about the signs of myelosuppression, including lethargy, fever, and bleeding, and instruct them to seek immediate veterinary care if these occur.

Challenge 5: Suspected Cardiac Involvement

Cardiac infiltration is a rare but serious complication of HES, as documented in a case of hypereosinophilic syndrome with cardiac infiltration and congestive heart failure in a cat (Journal of veterinary cardiology, 2022). Perform echocardiography in any cat with HES that develops respiratory signs, exercise intolerance, or arrhythmias. If cardiac involvement is confirmed, manage congestive heart failure with standard therapy including diuretics, ACE inhibitors, and pimobendan as needed. Aggressively treat the underlying HES with corticosteroids and consider adding hydroxyurea or imatinib. Refer to a veterinary cardiologist for ongoing management.

Practical Implementation Steps for the Veterinary Practice

Step 1: Establish a Baseline at Diagnosis

Before initiating therapy, document the following baseline values: complete blood count with differential, serum biochemistry profile, urinalysis, fecal examination, heartworm test, thoracic radiographs, abdominal ultrasound, bone marrow aspirate, and tissue biopsies from affected organs. This comprehensive baseline allows accurate staging and provides a reference for monitoring disease progression.

Step 2: Initiate Corticosteroid Therapy

Start prednisolone at 2 to 4 mg per kg per day orally, divided into two doses. Use the higher end of the dose range for cats with severe clinical signs or extensive organ involvement. Administer with food to reduce gastrointestinal upset. Instruct owners to monitor for side effects and report any concerns.

Step 3: Schedule Recheck Visits

Schedule the first recheck visit at two weeks, then at four weeks, then monthly until the cat is stable. At each visit, perform a physical examination, record the clinical score, measure body weight, and obtain a CBC. Adjust the corticosteroid dose based on response.

Step 4: Implement the Response Stratification at Four Weeks

At the four-week recheck, categorize the cat as a complete responder, partial responder, or non-responder using the criteria described above. Document the category in the medical record and communicate the treatment plan to the owner.

Step 5: Initiate Second-Line Therapy When Indicated

For partial responders who do not improve with dose escalation and for all non-responders, initiate hydroxyurea at 10 to 15 mg per kg per day orally. Monitor CBC every two weeks for the first two months. If hydroxyurea is ineffective or not tolerated, consider imatinib at 5 to 10 mg per kg per day orally, though availability and cost may be limiting factors.

Step 6: Long-Term Monitoring

Once the cat is stable on a maintenance regimen, schedule recheck visits every one to three months. Perform a CBC at each visit and a serum biochemistry profile every three to six months. Repeat thoracic radiographs and abdominal ultrasound every six to twelve months or if clinical signs change.

Common Failure Patterns in Treatment Implementation

Failure to Document Baseline Values: Without complete baseline data, it is impossible to accurately assess treatment response or detect disease progression. Always perform a full diagnostic workup before initiating therapy.

Inadequate Corticosteroid Dosing: Using subtherapeutic doses of corticosteroids is a common cause of treatment failure. Start at immunosuppressive doses and adjust based on response.

Premature Dose Reduction: Tapering corticosteroids too quickly often leads to relapse. Follow a gradual tapering schedule and monitor closely.

Ignoring Owner Reports: Owners are the best source of information about the cat's clinical status between visits. Take owner reports of changes in appetite, activity, or stool quality seriously and adjust the treatment plan accordingly.

Delaying Second-Line Therapy: Waiting too long to add hydroxyurea or imatinib in partial or non-responders allows disease progression and organ damage. Escalate therapy promptly when indicated.

Professional Escalation Criteria

Refer to a veterinary internist or oncologist in the following situations:

Difficulty differentiating HES from eosinophilic leukemia despite bone marrow examination
Persistent non-response to corticosteroids and second-line therapy
Development of severe side effects that limit treatment options
Suspected cardiac involvement requiring specialist management
Evidence of concurrent neoplasia, particularly lymphoma
Need for advanced imaging or interventional procedures

Welfare and Safety Context

Feline hypereosinophilic syndrome is a progressive, potentially life-threatening condition that causes significant morbidity. Affected cats experience chronic gastrointestinal signs, respiratory difficulty, and skin lesions that impair quality of life. Treatment aims to control clinical signs and slow disease progression, but cure is not achievable. Owners should be counseled about the guarded prognosis and the need for lifelong therapy and monitoring.

The World Organisation for Animal Health provides guidelines for animal health and welfare that emphasize the importance of timely diagnosis, appropriate treatment, and humane endpoints (Animal Health and Welfare, World Organisation for Animal Health). When treatment is no longer effective or side effects become intolerable, euthanasia should be considered to prevent suffering.

Cats receiving immunosuppressive doses of corticosteroids are at increased risk of infections, including urinary tract infections, respiratory infections, and opportunistic fungal infections. Monitor for signs of infection and treat promptly. Avoid live vaccines in cats receiving immunosuppressive therapy.

Hydroxyurea and imatinib are chemotherapeutic agents with potential teratogenic effects. Handle these medications with care, using gloves when administering oral doses. Advise owners to keep these medications out of reach of children and pets.

Summary of Practical Recommendations

Use a structured response stratification system to guide treatment decisions
Maintain a standardized record system for disease monitoring
Prioritize clinical response over laboratory values when they diverge
Taper corticosteroids gradually to minimize relapse
Add second-line therapy promptly in partial or non-responders
Monitor for side effects and adjust therapy accordingly
Refer to specialists when diagnostic or therapeutic challenges arise
Counsel owners about the guarded prognosis and need for lifelong care
Consider humane endpoints when treatment is no longer effective

Practical Decision Framework for Managing Feline Hypereosinophilic Syndrome

Treatment Response Stratification and Escalation Protocol

Response Categories and Treatment Tiers

Record System for Disease Monitoring

Maintain a standardized record for each cat with HES to track disease progression and treatment response. The following elements should be documented at each recheck visit:

Corticosteroid Dose: Record the current prednisolone dose in mg per kg per day or every other day. Note any dose changes and the reason for the change.

Second-Line Therapy Details: If using hydroxyurea or imatinib, record the dose, frequency, and any dose adjustments. Note the date of initiation and the reason for adding the medication.

Imaging Findings: Record the results of any imaging studies performed, including thoracic radiographs, abdominal ultrasound, or echocardiography. Note changes from previous studies.

Troubleshooting Common Management Challenges

Challenge 1: Persistent Eosinophilia Despite Clinical Improvement

Challenge 2: Relapse During Corticosteroid Tapering

Challenge 3: Poor Tolerance of Corticosteroids

Cats that develop significant side effects from corticosteroids, such as diabetes mellitus, severe polyuria and polydipsia, or behavioral changes, require dose reduction or alternative therapy. Measure blood glucose and urine glucose at each recheck visit. If diabetes develops, manage with insulin therapy and reduce the corticosteroid dose as much as possible. Consider adding hydroxyurea or imatinib early to allow corticosteroid dose reduction. In some cases, switching to a different corticosteroid formulation, such as dexamethasone, may reduce side effects, though this should be done cautiously and with monitoring.

Challenge 4: Myelosuppression from Hydroxyurea

Challenge 5: Suspected Cardiac Involvement

Practical Implementation Steps for the Veterinary Practice

Step 1: Establish a Baseline at Diagnosis

Step 2: Initiate Corticosteroid Therapy

Step 3: Schedule Recheck Visits

Step 4: Implement the Response Stratification at Four Weeks

Step 5: Initiate Second-Line Therapy When Indicated

Step 6: Long-Term Monitoring

Common Failure Patterns in Treatment Implementation

Inadequate Corticosteroid Dosing: Using subtherapeutic doses of corticosteroids is a common cause of treatment failure. Start at immunosuppressive doses and adjust based on response.

Premature Dose Reduction: Tapering corticosteroids too quickly often leads to relapse. Follow a gradual tapering schedule and monitor closely.

Delaying Second-Line Therapy: Waiting too long to add hydroxyurea or imatinib in partial or non-responders allows disease progression and organ damage. Escalate therapy promptly when indicated.

Professional Escalation Criteria

Refer to a veterinary internist or oncologist in the following situations:

Difficulty differentiating HES from eosinophilic leukemia despite bone marrow examination
Persistent non-response to corticosteroids and second-line therapy
Development of severe side effects that limit treatment options
Suspected cardiac involvement requiring specialist management
Evidence of concurrent neoplasia, particularly lymphoma
Need for advanced imaging or interventional procedures

Welfare and Safety Context

Summary of Practical Recommendations

Use a structured response stratification system to guide treatment decisions
Maintain a standardized record system for disease monitoring
Prioritize clinical response over laboratory values when they diverge
Taper corticosteroids gradually to minimize relapse
Add second-line therapy promptly in partial or non-responders
Monitor for side effects and adjust therapy accordingly
Refer to specialists when diagnostic or therapeutic challenges arise
Counsel owners about the guarded prognosis and need for lifelong care
Consider humane endpoints when treatment is no longer effective

Frequently Asked Questions

What is the difference between feline hypereosinophilic syndrome and eosinophilic leukemia?

Hypereosinophilic syndrome is characterized by persistent, severe eosinophilia with eosinophilic infiltration of multiple organs, but without blast cells in blood or bone marrow. Eosinophilic leukemia involves clonal proliferation of eosinophil precursors with blast cells and dysplastic changes, and carries a poorer prognosis.

How is feline hypereosinophilic syndrome diagnosed?

Diagnosis requires a complete blood count showing persistent severe eosinophilia, bone marrow aspirate to rule out leukemia, and histopathology of affected tissues to confirm eosinophilic infiltration. Additional testing to rule out parasitic, allergic, and neoplastic causes is essential.

What organs are most commonly affected in feline hypereosinophilic syndrome?

The gastrointestinal tract is most commonly affected, followed by the respiratory system and skin. Cardiac involvement is less common but has been reported and can lead to congestive heart failure.

What is the treatment for feline hypereosinophilic syndrome?

Corticosteroids are the mainstay of therapy. Hydroxyurea or imatinib may be used as second-line therapies in cats that do not respond adequately to corticosteroids. Supportive care including dietary modification and symptomatic treatment is also important.

What is the prognosis for cats with hypereosinophilic syndrome?

The prognosis is guarded to poor. Most cats require lifelong therapy, and the disease is often progressive. Survival times vary, with some cats living months to years with appropriate management.

Can feline hypereosinophilic syndrome be associated with cancer?

Yes, a paraneoplastic form of hypereosinophilic syndrome has been described in association with lymphocytic intestinal lymphoma. Thorough diagnostic investigation for underlying neoplasia is warranted.

How should cats on hydroxyurea be monitored?

Cats on hydroxyurea require regular CBC monitoring to detect myelosuppression, including neutropenia and thrombocytopenia. Liver enzymes should also be monitored. The dose is adjusted based on CBC results.

When should a cat with hypereosinophilic syndrome be referred to a specialist?

Referral to a veterinary internist or oncologist is recommended when there is difficulty differentiating HES from other eosinophilic disorders, poor response to corticosteroids, need for second-line therapies, development of severe side effects, or suspected cardiac involvement or concurrent neoplasia.

Related Veterinary Guides

References and Further Reading

www.merckvetmanual.com
catvets.com
www.acvim.org
Merck Veterinary Manual. Merck Veterinary Manual.
Animal Health and Welfare. World Organisation for Animal Health.
Feline paraneoplastic hypereosinophilic syndrome associated with lymphocytic intestinal lymphoma.. Brazilian journal of veterinary medicine, 2026.
Pathology in Practice.. Journal of the American Veterinary Medical Association, 2017.
Hypereosinophilic syndrome in a cat.. The Canadian veterinary journal = La revue veterinaire canadienne, 1996.
Hypereosinophilic syndrome in two cats.. The Journal of veterinary medical science, 2008.
Hypereosinophilic syndrome with cardiac infiltration and congestive heart failure in a cat.. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2022.
Investigation of hypereosinophilia and potential treatments.. The Veterinary clinics of North America. Small animal practice, 2003.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.